ENTITY
Mesoblast Ltd

Mesoblast Ltd (MSB AU)

43
Analysis
Health CareAustralia
Mesoblast Limited provides biomedical services. The Company develops drugs for cardiovascular diseases, oncology, hematology, and spine orthopedic disorders treatment. Mesoblast conducts its business worldwide.
more
Refresh
bullishMesoblast Ltd
16 Nov 2021 15:56

Mesoblast (MSB AU): Gets Closer to FDA Approval Pathways on Positive Phase 3 Clinical Trial Data

Mesoblast presented positive phase 3 results in chronic heart failure patients. The product candidate has the potential to become blockbuster drug,...

Logo
212 Views
Share
05 Jul 2021 12:51

ASX200 Sep21 Index Rebalance Preview: Large Impact Names

We see 3 potential changes to the ASX200 at the Sep rebalance with CNI, PNI and SLK being included and NXL, NRW and GEM being deleted. Passive...

Logo
408 Views
Share
bullishAllkem Ltd
28 May 2021 05:50

ASX200 Index Rebalance Preview: Gold Miners Shining

We see 3 potential changes to the ASX200 in the June review. All inclusions/exclusions have over 3 days of ADV to trade from passive funds. Short...

Logo
311 Views
Share
bullishCodan
01 Mar 2021 06:18

ASX200 Index Rebalance Preview: Three Potential Changes & Some Close Names

We see three potential changes to the ASX200 in the March review while there are another two close adds/deletes. High short interest on the...

Logo
409 Views
Share
bullishMesoblast Ltd
01 Jul 2020 19:34Issuer-paid

Mesoblast - COVID-19 ARDS Phase III readout later this year

Mesoblast has initiated a 300-patient randomized, controlled Phase III trial of remestemcel-L (Ryoncil for the acute graft versus host disease...

Share
x